1294504-68-9

Basic information

• Product Name: CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-
• Synonyms: CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-;CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-9;(R)-N-(1-(3-(benzyloxy)-2-hydroxypropyl)-2-(1-(benzyloxy)-2-methylpropan-2-yl)-6-fluoro-1H-indol-5-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide
• CAS NO: 1294504-68-9
• Molecular Formula: C₄₀H₃₉F₃N₂O₆
• Molecular Weight: 700.7426696
• Mol File: 1294504-68-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-(1294504-68-9)
• EPA Substance Registry System: CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]-(1294504-68-9)

Safety Data

• Hazardous Substances Data: 1294504-68-9(Hazardous Substances Data)

Usage

General Description

The chemical "Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-dimethyl-2-(phenylmethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylmethoxy)propyl]-1H-indol-5-yl]-" is a complex compound consisting of a cyclopropanecarboxamide backbone with several substituents. It contains a difluoro-benzodioxol ring, a dimethyl-phenylmethoxyethyl group, a fluoro-hydroxy-phenylmethoxypropyl group, and an indolyl ring. CyclopropanecarboxaMide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[2-[1,1-diMethyl-2-(phenylMethoxy)ethyl]-6-fluoro-1-[(2R)-2-hydroxy-3-(phenylMethoxy)propyl]-1H-indol-5-yl]- is likely to have specific biological activities and could be used potentially for pharmacological purposes. The combination of different functional groups in this chemical suggests that it may have diverse interactions with biological systems and could be useful for further research and development in the field of medicinal chemistry.

Upstream product

• 2369-13-3 3-fluoro-4-nitroaniline 
• 33070-32-5 5-bromo-2,2-difluoro-2H-1,3-benzodioxole 
• 656-46-2 2,2-difluoro-1,3-benzodioxole-5-carboxylic acid 
• 72768-97-9 (2,2-difluoro-1,3-benzodioxol-5-yl)methanol 
• 476473-97-9 5-chloromethyl-2,2-difluoro-benzo[1,3]dioxole 
• 862574-87-6 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarbonitrile 
• 862574-88-7 1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropane-1-carboxylic acid 
• 68119-31-3 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)acetonitrile 
• 952664-69-6 2-bromo-5-fluoro-4-nitroaniline 
• 1004294-65-8 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane carboxylic acid chloride 
• 1294504-67-8 (2R)-1-{5-amino-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-1H-indol-1-yl}-3-(benzyloxy)propan-2-ol 
• 1294504-65-6 (4-(benzyloxy)-3,3-dimethylbut-1-ynyl)trimethylsilane 
• 1092536-54-3 [{(2,2-dimethylbut-3-yn-1-yl)oxy}methyl]benzene 
• 1335233-51-6 (2,2-difluoro-1,3-benzodioxol-5-yl)-1-ethylacetate acetonitrile 

Downstream Products

• 1152311-62-0 (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 

Relevant articles and documents

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Tezacaftor intermediate II preparation method

The invention provides a Tezacaftor intermediate II preparation method, which comprises: carrying out a reaction on a compound represented by a formula I and used as a reaction raw material under theactions of a catalyst and an alkali in an organic solvent to obtain a Tezacaftor intermediate II, wherein the reaction equation is defined in the specification, and the catalyst of the reaction is a mixture of a copper salt and N-methylpyrrolidone. According to the present invention, by using the completely-new CuI/NMP catalytic system, the problem that the Pd reagent is used in the prior art is eliminated so as to greatly reduce the production cost, the influence of the residual metal palladium on the drug Tezacaftor can be avoided, and importantly the reaction yield of the key step for Tezacaftor intermediate II synthesis is significantly increased by using the completely-new CuI/NMP catalytic system so as to greatly increase the Tezacaftor intermediate II production efficiency and further reduce the production cost.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.